Based on the forecasted data, antiarrhythmic medicine sales in Finland remain consistent at 0.1% of total sales for the years 2024, 2025, and 2026, followed by a sharp decline to 0% in 2027 and 2028. This indicates no growth within the initial three years, followed by a complete cessation of sales in the subsequent two years.
Future Trends: The data suggests a potential phase-out of antiarrhythmic medicines or a significant shift toward alternative treatments. Factors to watch include regulatory changes, advancements in alternative therapies, and market dynamics influencing pharmaceutical demand in Finland.
